Friday, 16 October 2026European Markets

OCEANTEAM Stock Is 9% Down At Session Start Today

Loading stream...

(VIANEWS) - Shares of OCEANTEAM (Oslo Børs Benchmark Index_GI: OTS.OL) fell 9.28% to kr1.32 at 10:39 EST on Friday, following the last session's upward trend. Oslo Børs Benchmark Index_GI is sliding 1.33% to kr1,217.11, after four successive sessions in a row of losses. This seems, at the moment, an all-around negative trend trading session today.

OCEANTEAM's last close was kr1.47, 74.12% under its 52-week high of kr5.68.

About OCEANTEAM

Oceanteam ASA operates as a subsea and offshore services company in Europe. It provides equipment for offshore cable laying, umbilical installations, handling of subsea cables, and on- and offshore storage and transport. The company also rents turntables, tensioners, reels, demountable carousels, and other cable handling equipment. It serves renewable, and oil and gas industries. The company was formerly known as Oceanteam Shipping ASA and changed its name to Oceanteam ASA in December 2015. Oceanteam ASA was incorporated in 2005 and is headquartered in Bærum, Norway.

Earnings Per Share

As for profitability, OCEANTEAM has a trailing twelve months EPS of kr-11.078.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -13.71%.

More news about OCEANTEAM (OTS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com